NasdaqCM:IDXG

Stock Analysis Report

Interpace Diagnostics Group

Executive Summary

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic alterations associated with gastrointestinal, endocrine, and lung cancers.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Interpace Diagnostics Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.1%

NasdaqCM:IDXG

-1.2%

US Healthcare

-0.02%

US Market


1 Year Return

-53.7%

NasdaqCM:IDXG

-9.4%

US Healthcare

1.6%

US Market

IDXG underperformed the Healthcare industry which returned -8.4% over the past year.

IDXG underperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

IDXGIndustryMarket
7 Day1.1%-1.2%-0.02%
30 Day3.8%-2.2%2.7%
90 Day-1.2%-1.5%1.4%
1 Year-53.7%-53.7%-8.0%-9.4%3.8%1.6%
3 Year-53.4%-53.4%28.7%23.5%45.2%35.8%
5 Year-96.8%-96.8%62.7%53.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is Interpace Diagnostics Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Interpace Diagnostics Group undervalued based on future cash flows and its price relative to the stock market?

0.96x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Interpace Diagnostics Group to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Interpace Diagnostics Group to establish if it is available at substantial discount.


Price Based on Earnings

Interpace Diagnostics Group is loss making, we can't compare its value to the US Healthcare industry average.

Interpace Diagnostics Group is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Interpace Diagnostics Group, we can't assess if its growth is good value.


Price Based on Value of Assets

Interpace Diagnostics Group is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Interpace Diagnostics Group expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

72.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Interpace Diagnostics Group's revenue is expected to grow significantly at over 20% yearly.

Interpace Diagnostics Group's earnings are expected to grow significantly at over 20% yearly.

Interpace Diagnostics Group's revenue growth is expected to exceed the United States of America market average.

Interpace Diagnostics Group's earnings growth is expected to exceed the United States of America market average.

Interpace Diagnostics Group's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Interpace Diagnostics Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Interpace Diagnostics Group performed over the past 5 years?

8.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Interpace Diagnostics Group does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Interpace Diagnostics Group's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Interpace Diagnostics Group's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Interpace Diagnostics Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Interpace Diagnostics Group has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Interpace Diagnostics Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Interpace Diagnostics Group's financial position?


Financial Position Analysis

Interpace Diagnostics Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Interpace Diagnostics Group's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Interpace Diagnostics Group has no debt.

Interpace Diagnostics Group currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Interpace Diagnostics Group has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Interpace Diagnostics Group has less than a year of cash runway based on current free cash flow.

Interpace Diagnostics Group has less than a year of cash runway if free cash flow continues to reduce at historical rates of -6.2% each year.


Next Steps

Dividend

What is Interpace Diagnostics Group's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Interpace Diagnostics Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Interpace Diagnostics Group's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Interpace Diagnostics Group has not reported any payouts.

Unable to verify if Interpace Diagnostics Group's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Interpace Diagnostics Group has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Interpace Diagnostics Group's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Jack Stover (66yo)

3.3yrs

Tenure

US$1,307,880

Compensation

Mr. Jack E. Stover, CPA has been the Chief Executive Officer and President of Interpace Diagnostics Group, Inc. since June 21, 2016. Mr. Stover has been Chief Executive Officer of Zebec Therapeutics LLC (Z ...


CEO Compensation Analysis

Jack's remuneration is higher than average for companies of similar size in United States of America.

Jack's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.3yrs

Average Tenure

58.5yo

Average Age

The tenure for the Interpace Diagnostics Group management team is about average.


Board Age and Tenure

3.7yrs

Average Tenure

65.5yo

Average Age

The tenure for the Interpace Diagnostics Group board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jack Stover (66yo)

    CEO, President & Director

    • Tenure: 3.3yrs
    • Compensation: US$1.31m
  • Greg Richard (52yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 5.4yrs
    • Compensation: US$619.24k
  • Sydney Finkelstein

    Chief Scientific Officer

    • Tenure: 0yrs
  • Patrick Kane

    VP & Corporate Controller

    • Tenure: 10.3yrs
  • Jim Early (65yo)

    CFO, Secretary & Treasurer

    • Tenure: 2.9yrs
    • Compensation: US$489.27k
  • Thomas Freeburg (51yo)

    Chief Accounting Officer

    • Tenure: 1.5yrs
  • Glenn Gershon

    Senior Vice President of Operations

    • Tenure: 0yrs

Board Members

  • Joe Keegan (65yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: US$77.13k
  • Steve Sullivan (72yo)

    Chairman of the Board

    • Tenure: 3.7yrs
    • Compensation: US$87.13k
  • Eric Lev

    Director

    • Tenure: 0.2yrs
  • Jack Stover (66yo)

    CEO, President & Director

    • Tenure: 3.3yrs
    • Compensation: US$1.31m
  • Felice Schnoll-Sussman (49yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$57.13k

Company Information

Interpace Diagnostics Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Interpace Diagnostics Group, Inc.
  • Ticker: IDXG
  • Exchange: NasdaqCM
  • Founded: 1986
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$29.724m
  • Shares outstanding: 38.20m
  • Website: https://www.interpacediagnostics.com

Number of Employees


Location

  • Interpace Diagnostics Group, Inc.
  • Morris Corporate Center 1
  • Building C
  • Parsippany
  • New Jersey
  • 7054
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IDXGNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 1998
PF41DB (Deutsche Boerse AG)YesCommon StockDEEURMay 1998

Biography

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic alterations associated with gastrointestinal, endocrine, and lung cancers. It offers PancraGEN, a  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 23:38
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.